Caphosol® Mouth Rinse is suitable for temporary or persistent dryness of the mouth and throat. It can be used as an adjunct to standard oral care for the prevention and treatment of oral mucositis caused by radiotherapy or high dose chemotherapy. Caphosol® has been approved for marketing in 48 countries around the world currently and has demonstrated clinical efficacy and safety for the prevention and treatment of oral mucositis.
The incidence of oral mucositis varies among cancer patients. According to the data from cancer care associations, oral mucositis affects almost all patients receiving radiation therapy for head and neck cancer, nearly 80% of patients receiving hematopoietic stem cell transplantation, and 40% of patients receiving standard chemotherapy.